Welcome to our dedicated page for CareDx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on CareDx stock.
CareDx, Inc. (NASDAQ: CDNA) is at the forefront of transforming transplant patient care through its innovative surveillance management solutions. Dedicated to improving the lives of organ transplant patients, CareDx leverages the latest in genomics and bioinformatics technology combined with rigorous clinical evidence derived from trials and registries.
CareDx offers a suite of precision medicine solutions aimed at enhancing both pre- and post-transplant care. One of its flagship products, AlloSure®, is the first and only non-invasive blood test that directly measures allograft injury. This next-generation sequencing (NGS) based test detects donor-derived cell-free DNA (dd-cfDNA), providing clinicians with a powerful tool to identify organ injury and the probability of active rejection, particularly in kidney transplant patients.
The company's portfolio also includes AlloMap Heart, AlloSure Heart, and AlloSure Lung, which are dd-cfDNA solutions designed for heart and lung transplant recipients. These products underscore CareDx’s commitment to offering clinically differentiated, high-value healthcare solutions that span the entire transplant journey.
CareDx generates the majority of its revenue from the United States, with a significant portion coming from its testing services. Its product suite not only addresses the critical needs of transplant patients but also supports healthcare providers in delivering better patient outcomes through genomics-based information.
Recent achievements include the continued expansion of their product line and partnerships with leading healthcare institutions to further validate and implement their innovative diagnostic solutions. These efforts position CareDx as a leader in the field of transplant diagnostics and surveillance.
CareDx, Inc. (Nasdaq: CDNA) has partnered with the International Society for Heart and Lung Transplantation (ISHLT) to introduce the Innovation Challenge Award. This initiative aims to promote research on the clinical utility of donor-derived cell-free DNA (dd-cfDNA) and gene expression profiling (GEP) methodologies in heart and lung transplants. Applications are open until January 31, 2022, with finalists presenting at the ISHLT 2022 Annual Meeting in April. Dr. Sham Dholakia expressed the importance of these non-invasive techniques for improving long-term transplant patient outcomes.
CareDx, Inc. has initiated the ALAMO registry, enrolling 1,000 lung transplant patients across the U.S. to enhance clinical decision-making. This study aims to evaluate LungCare's capability to detect transplant infections and rejections. Utilizing tests like AlloSure, AlloMap, and AlloID, the registry will track outcomes over three years, focusing on survival rates and severe infections. The development of multimodality diagnostics is expected to provide significant benefits in managing lung transplant recipients, potentially reducing the need for invasive biopsies.
CareDx, Inc. has partnered with the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) to utilize their pediatric patient registry for a long-term outcomes study of AlloSure, a donor-derived cell-free DNA service aimed at improving organ transplant care in pediatric kidney patients. The study will track data for five years or until its conclusion, validating the utility of dd-cfDNA testing in managing long-term patient outcomes. This collaboration highlights CareDx's commitment to providing innovative solutions for pediatric transplant patients.
CareDx announced that over 80,000 organ transplant patients have utilized its AlloSure and AlloMap tests for post-transplant care. These tests are widely used, with over 90% of heart transplant centers and 70% of kidney transplant centers employing AlloSure and AlloMap. The recent launch of AlloSure Lung has also seen adoption in over 20 centers. CEO Reg Seeto emphasized the importance of active monitoring for transplant recipients, highlighting patient testimonials that illustrate the tests' positive impact on patient care.
CareDx (Nasdaq: CDNA) has initiated the TEAMMATE study, the largest digital study to assess the AlloCare app's impact on organ transplant patients. Enrolling 4,000 participants from over 100 transplant centers, the study will analyze 90-day readmission rates and other health metrics across various organ transplants. The AlloCare app aids in medication management and tracking vital signs, aiming to improve patient adherence and outcomes. The study is crucial for evaluating whether technology can enhance transplant care.
CareDx, a precision medicine company focused on transplant patients, announced its participation in the 12th Annual Jefferies London Healthcare Conference and the 4th Annual Evercore ISI HealthCONx Conference. The management team will present at these events, with a pre-recorded fireside chat available starting November 18, 2021, at 8:00 AM GMT, and a live chat on December 1, 2021, at 2:15 PM EST. Interested investors can listen to the webcasts via the company’s investor relations website.
CareDx has announced its acquisition of MedActionPlan, enhancing its technology suite aimed at improving medication adherence for transplant patients. MedActionPlan's platforms, including MedActionPlan PRO and MyMedSchedule Plus, are utilized in over 100 healthcare systems. This strategic integration aligns with CareDx's mission to enhance patient outcomes through better medication management post-transplant. The acquisition is expected to amplify CareDx's reach and strengthen its offerings in the transplant medication management space.
CareDx, Inc. (Nasdaq: CDNA) announces the successful integration of TxAccess with the University of Alabama at Birmingham (UAB) Comprehensive Transplant Institute, expanding its reach to over 500 dialysis centers. TxAccess simplifies patient referrals to transplant waitlists, streamlining communication between transplant centers, nephrologists, and dialysis organizations. Over 38,000 referrals have been managed through this service, highlighting its effectiveness in improving patient coordination.
CareDx announced its participation in the American Society of Nephrology (ASN) Kidney Week 2021, showcasing key findings related to its AlloSure test.
The company will present two abstracts, emphasizing the test's role in kidney transplant patient management, including insights on donor-derived cell-free DNA. Additionally, CareDx is hosting a Transplant Innovation Day on November 5, featuring discussions on xenotransplantation and validation data for AlloMap Kidney.
The CEO highlighted the significance of these advancements in transplantation science.
FAQ
What is the current stock price of CareDx (CDNA)?
What is the market cap of CareDx (CDNA)?
What does CareDx, Inc. specialize in?
What is AlloSure®?
Which organs do CareDx's products focus on?
Where does CareDx generate most of its revenue?
What are some key products offered by CareDx?
How does CareDx support transplant patients?
What technology does CareDx use in its diagnostics?
Does CareDx collaborate with other healthcare institutions?
What kind of clinical evidence does CareDx generate?
What makes CareDx a leader in transplant diagnostics?
